Agios Pharmaceuticals vs ARS Pharmaceuticals
AGIO and SPRY side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AGIO and SPRY compare
Agios Pharmaceuticals is the larger company, worth 4.9 times as much as ARS Pharmaceuticals ($1.9B against $387M).
Agios Pharmaceuticals grew revenue faster over the last twelve months (214% versus −14.5% for ARS Pharmaceuticals).
ARS Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of −164% compared with −265% at Agios Pharmaceuticals.
Agios Pharmaceuticals scores higher on the StockData Score (13 against 9 for ARS Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AGIO | SPRY |
|---|---|---|
| Size and price | ||
| Market cap | $1.9B | $387M |
| Share price | $31.59 | $3.89 |
| Change, 1 year | −27.6% | −56.5% |
| Change, 5 years | −17.3% | −52.7% |
| Beta (5Y) | 1.41 | 1.42 |
| Employees | 539 | 158 |
| StockData Score | ||
| Total score | 13 (better) | 9 |
| Valuation score | 2 (better) | 1 |
| Growth score | 3 (better) | 2 |
| Performance score | 2 (better) | 1 |
| Health score | 6 (better) | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 13.4× | 3.2× (better) |
| P/B | 1.9× | – |
| FCF yield | −17.8% (better) | −47.3% |
| Fair value | $32.10 | – |
| Margin of safety | 1.6% | – |
| Growth | ||
| Revenue growth (TTM) | 214% (better) | −14.5% |
| Profitability | ||
| Gross margin | 93.8% | – |
| Operating margin | −298% | −161% (better) |
| Net margin | −265% | −164% (better) |
| FCF margin | −239% | −150% (better) |
| Return on equity | −32.9% (better) | −295% |
| Return on invested capital | −1169% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Current ratio | 9.69 (better) | 3.25 |
| Altman Z-score | 11.86 (better) | −3.05 |
| Piotroski F-score | 1 | 2 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 111% | 91.2% |
| Held by insiders | 1.1% | 46.7% |
| Insider net buying, 12 months | −$4.9M | −$284K (better) |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 11.1% | 35.9% |
Go deeper
- AGIO stock overview
- AGIO income statement
- AGIO valuation and score
- SPRY stock overview
- SPRY income statement
- SPRY valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.